Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Perry

Transplant Surgery Seattle, WA Medical Doctor

NPI 1639503386 CMS profile 7222306

1124 Columbia St Ste 600, Seattle, WA 98104

Open in the dashboard

General payments

$1,246

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Perry of Seattle, WA is reported in the CMS Open Payments database as having received $1,246 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 5
2024 General $138 1
2022 General $20 1
2020 General $239 2
2019 General $141 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Perry
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Andrew Perry were reported at $709. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Andrew Perry Transplant Surgery median Middle half National median
2019 $141 $203 $77–$1,249 $163
2020 $239 $149 $52–$1,366 $114
2021 $0 $168 $73–$2,008 $132
2022 $20 $213 $94–$1,464 $149
2023 $0 $262 $93–$1,458 $160
2024 $138 $354 $126–$2,252 $164
2025 $709 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $709 5 payments
  2. Abiomed $141 1 payment
  3. Mallinckrodt Hospital Products Inc. $138 1 payment
  4. Intercept Pharmaceuticals, Inc. $121 1 payment
  5. Ethicon US, LLC $117 1 payment
  6. Gilead Sciences, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $672 3 payments
  2. Food and Beverage $574 7 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $709 5 payments
  2. Impella $141 1 payment
  3. TERLIVAZ $138 1 payment
  4. OCALIVA $121 1 payment
  5. VISTASEAL $117 1 payment
  6. Surgicel Powder $117 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

906

Median for General Surgery: 59

Drug cost

$52,480

Median for General Surgery: $393

Branded share of claims

12.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entecavir Generic 24 $10,569
Atovaquone Generic 26 $9,721
Tacrolimus Generic 125 $9,433
Valganciclovir Hcl Generic 69 $8,831
Ursodiol Generic 70 $3,985
Mycophenolic Acid Mycophenolate Sodium Brand 41 $3,942
Mycophenolate Mofetil Generic 44 $1,470
Ultra-Fine Mini Pen Needle Pen Needle, Diabetic Brand 13 $880
Calcitriol Generic 54 $868
Pantoprazole Sodium Generic 144 $696

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$77,761

Medicare's payments for the services billed

Medicare patients

50

Average age 60

Services billed

194

20 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 44%
Arthritis 38%
Ischemic heart disease 30%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record